Author:
Khurelbat Daariimaa,Dorj Gereltuya,Bayarsaikhan Enkhtuul,Chimedsuren Munkhdelger,Sanjjav Tsetsegmaa,Morimoto Takeshi,Morley Michael,Morley Katharine
Abstract
Abstract
To determine the prevalence of substandard drugs in urban (Ulaanbaatar) and rural (selected provinces) areas of Mongolia, samples of 9 common, therapeutically important drugs were collected from randomly selected drug outlets in Ulaanbaatar and 4 rural provinces by “mystery shoppers”. Samples were analyzed by visual inspection, registration status, and biochemical analysis. Samples failing to meet all Pharmacopeia quality tests were considered substandard.
In the rural provinces, 69 out of 388 samples were substandard, giving an estimated prevalence of substandard drugs of 17.8% (95% CI: 14.1-22.0). There were 85 unregistered samples, giving a prevalence estimate of unregistered drugs of 21.9%. (95% CI: 17.9-26.3). In the urban Ulaanbaatar districts, 112 out of 848 samples were substandard, giving an estimated prevalence of substandard drugs of 13.2% (95% CI: 11.0-15.7). There were 150 unregistered samples, giving a prevalence estimate of unregistered drugs of 17.7% (95% CI: 15.2-20.4).
In the rural provinces, 35 out of 85 (41.2%) unregistered samples were substandard; whereas 34 out of 303 (11.2%) registered samples were substandard. (p < 0.0001) In the urban districts, 18 out of 150 (12.0%) unregistered samples were substandard, whereas 94 out of 698 registered were substandard. (13.5%) (p = 0.6).
The prevalence of substandard and unregistered drugs is higher in rural provinces. There is a significant association between substandard and unregistered drugs in the provinces but not in the urban districts. The underlying causes for substandard drugs need to be further investigated in order to help formulate strategies to improve pharmacovigilance and the drug supply quality in Mongolia.
Publisher
Springer Science and Business Media LLC
Reference17 articles.
1. Abdelkrim S: Quality Control and Quality Assurance of Medicines in Mongolia. World Bank, Health Sciences University of Mongolia; 2009. Available from Mongolia Ministry of Health
2. Almuzaini T, Choonara I, Sammons H: Substandard and counterfeit medicines: a systematic review of the literature. BMJ Open 2013, 3: e002923.
3. Attaran A, Barry D, Basheer S, Bate R, Ben-ton D, Chauvin J, Garrett L, Kickbusch I, Kohler JC, Midha K, Newton PN, Nishtar S, Orhii P, McKee M: How to achieve international action on falsified and substandard medicines. BMJ (Clinical research ed) 2012 345: e7381. (Accessed October 21, 2014) http://researchonline.lshtm.ac.uk/768540/1/bmj.e7381.full.pdf
4. British Pharmacopoeia Vol. 2 Stationery Office, London; 2001.
5. Caudron JM, Ford N, Henkens M, Macé C, Kiddle-Monroe R, Pinel J: Substandard medicines in resource-poor settings: a problem that can no longer be ignored. Trop Med Int Health 2008, 13: 1062-1072. 10.1111/j.1365-3156.2008.02106.x
Cited by
12 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献